Posted 5th January 2026
Posted 3 weeks ago
By NHP Office
NHP Cellular Therapy Operational Group (CTG)
Learn more about the NHP Cellular Therapy Operational Group (CTG)
This section hosts publications (updates, reports and guidelines) by the NHP and its network partners and affiliates.
Posted 5th January 2026
Posted 19th November 2025
Posted 2 months ago
By Nhp
Posted 31st August 2025
Posted 5 months ago
By NHP Office
20250831 RCPath National Examiner's Good Practice in Sickle Cell Disease
The guidance provides good practice advice for medical examiners on recognising the impact of SCD in various contexts including deaths and coroner referrals.
Posted 11th August 2025
Posted 5 months ago
By NHP Office
Mortality Reporting Pathway
First iteration of the mortality reporting pathway for haemoglobinopathies.
Posted 21st November 2024
Posted 1 year ago
By NHP Office
NHP 2023/2024 Annual Report
The NHP activity report for 2023/2024 (published 21 November 2024) gives an overview of its core and partner-related activities.
Posted 19th November 2024
Posted 1 year ago
By NHP Office
New NHP Chair Announced – Dr Kate Gardner
Following the stepping down of Professor Baba Inusa, Dr Kate Gardner has been appointed the new NHP Chair.
Posted 21st October 2024
Posted 1 year ago
By Pfizer
Pfizer Shares Patient Letter re Voxelotor (Oxybryta®) Withdrawal
Pfizer Shares Patient Advice Regarding Immediate Withdrawal of Voxelotor (Oxybryta®)
Posted 10th October 2024
Posted 1 year ago
By NHP Office
Voxelotor (Oxbryta®) Withdrawal - NHP Patient Letter
Following the unforeseen Pfizer withdrawal of Voxelotor (Oxbryta®) Medication for Sickle Cell Disease on 25th September 2024, the NHP provided a letter assist affected Sickle Cell Disorder patients.
Posted 4th October 2024
Posted 1 year ago
By NHS England
NHS England on Oxbryta (Voxelotor) Withdrawal From the UK Market
NHS England sends a letter to centres regarding the 25.09.2024 withdrawal of Pfizer's Oxbryta (Voxelotor) drug for Sickle Cell Disorder.
Posted 9th September 2024
Posted 1 year ago
By NHS England
SOP- Casgevy (Exagamglogene Autotemcel) for Transfusion-dependent Thalassaemia
University College London have produced a Standard Operating Procedure (SOP) for the assessment and work up of exagamglogene autotemcel (Casgevy™) for transfusion-dependent beta-thalassaemia
Posted 19th June 2024
Posted 2 years ago
By NHP Office
World Sickle Cell Day 2024
For World Sickle Cell Awareness Day (19th June) 2024, we ask; 'Why try to reinvent the wheel?'
Posted 8th May 2024
Posted 2 years ago
By NHP Office
Posted 1st April 2024
Posted 2 years ago
By NHP Office
A Chapter Closes: Professor Baba Inusa Leaves the National Haemoglobinopathy Panel (NHP)
The Founding Chair of the NHP, Professor Baba Inusa, announces his departure from the NHS and his NHP Role in March 2024.
Posted 21st January 2024
Posted 2 years ago
By NHP Office
NHP 2022/2023 Annual Report
The NHP Annual Report is a summary of its activities and interactions.
